Triazolam

Generic Name
Triazolam
Brand Names
Halcion
Drug Type
Small Molecule
Chemical Formula
C17H12Cl2N4
CAS Number
28911-01-5
Unique Ingredient Identifier
1HM943223R
Background

Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

Indication

For the short-term treatment of insomnia.

Associated Conditions
Insomnia
Associated Therapies
Sedation
Clinical Trials
Related News

Oral Versus Intravenous Sedation for Ocular Procedures

First Posted Date
2017-08-11
Last Posted Date
2020-08-19
Lead Sponsor
Boston Medical Center
Target Recruit Count
327
Registration Number
NCT03246724
Locations
🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Methylphenidate
Drug: Triazolam
Drug: Placebo
First Posted Date
2016-07-06
Last Posted Date
2016-11-06
Lead Sponsor
Akili Interactive Labs, Inc.
Target Recruit Count
18
Registration Number
NCT02822937
Locations
🇺🇸

Clinical Trials of Texas, San Antonio, Texas, United States

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

First Posted Date
2013-06-27
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
59
Registration Number
NCT01888497
Locations
🇺🇸

NeuroTrials Research, Inc., Atlanta, Georgia, United States

🇺🇸

NeuroTrials Research Sleep Lab, Atlanta, Georgia, United States

🇺🇸

Miami Research Associates, South Miami, Florida, United States

and more 1 locations

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Esketamine
Drug: Placebo
Drug: Triazolam
First Posted Date
2013-01-31
Last Posted Date
2013-08-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
58
Registration Number
NCT01780259

Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption

Phase 1
Withdrawn
Conditions
Healthy Volunteers
Interventions
Drug: Triazolam
First Posted Date
2009-11-23
Last Posted Date
2016-04-06
Lead Sponsor
Pfizer
Registration Number
NCT01017926
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy